It’s a big drugmaker with a blockbuster immunology drug as its top-selling product. It pays an attractive dividend. And it faces some uncertainties. This description fits Amgen (NASDAQ:AMGN), but it applies just as well to Johnson & Johnson (NYSE:JNJ).
So far in 2018, Amgen has been the bigger winner for investors. The biotech stock is up more than 10% year to date, while J&J stock is down nearly 9%. But which of these two drug stocks is the better choice for long-term investors? Here’s how Amgen and Johnson & Johnson compare.
Image source: Getty Images.
The case for Amgen
Let’s first address the challenges Amgen faces. Sales for the company’s top-selling products are slipping. Enbrel competes in a crowded market. Neulasta now must battle head to head against a new biosimilar from Mylan. But Amgen also claims some rising stars that should help offset some of these declines.
Best Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)
- [By ]
Amgen’s (NASDAQ:AMGN) past is filled with excitement. The company rose to become one of the biggest biotechs in the world. It grew a product lineup with multiple blockbuster drugs. Over the last decade, Amgen’s share price has more than tripled. But the excitement appears likely to diminish considerably for Amgen — at least for the next few years.
- [By Logan Wallace]
Navellier & Associates Inc lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,176 shares of the medical research company’s stock after purchasing an additional 353 shares during the period. Navellier & Associates Inc’s holdings in Amgen were worth $4,278,000 at the end of the most recent reporting period.
- [By ]
This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV) , Amgen (AMGN) , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN) and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.
Best Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)
- [By George Budwell]
Shares of large-cap biotech Biogen (NASDAQ:BIIB) gained a healthy 15.2% in July, according to data from S&P Global Market Intelligence. What triggered this breakout?
- [By George Budwell]
Biotech heavyweight Biogen (NASDAQ:BIIB) has now lost over 13% of its value so far this year. To be fair, this year hasn’t been kind to biotechs in general, thanks to President Trump’s aggressive trade policies with China. But Biogen’s value has been declining at a far faster rate than the industry as a whole due to stiffer competition in the all-important multiple sclerosis (MS) space.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 2.85 million shares from the previous 3.59 million. The stock recently traded at $316.87, within a 52-week range of $249.17 to $388.67.
Best Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Cory Renauer]
After 16 years as a public company, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) finally got the go-ahead to launch its first product earlier this month. Onpattro is the first in a new class of drugs that alter gene expression, but Pfizer, Inc. (NYSE:PFE) just reported some impressive results with a possible competitor that works a lot differently.
- [By Cory Renauer]
Taking a medical breakthrough from concept through commercial success is like ascending a mountain that grows taller and more treacherous with every setback. It’s taken Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) 16 years to launch its first drug, so challenges have had plenty of time to take up positions along this company’s path to a successful first launch.
- [By Jim Crumly]
Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.
Best Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month’s Gain
Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
Transenterix Inc. (NYSE: TRXC) $3.46 77.84%
While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Ethan Ryder]
ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.